ArticleACS omega2025
Benzalkonium Chloride-Coated Iron Oxide Nanoparticles: Cytotoxic Potential on Murine Leydig Cells (TM3).
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents a novel nanocomplex, Mag-Bc, combining magnetite (Mag) and benzalkonium chloride (Bc). The objective was to evaluate the cytotoxic potential of Mag-Bc across three cell lines (TM3, VERO, and AML-12) and to assess its antiandrogenic effects specifically on TM3 cells. Physicochemical characterization confirmed the formation of partially oxidized magnetite and successful Bc coating, which conferred a positive charge to the nanoparticles. Viability assays on TM3 cells demonstrated no reduction below 70% at any dose or exposure time. Cellular internalization studies revealed efficient uptake of both coated and uncoated nanoparticles, indicating that the Bc coating did not impair cellular internalization. The nanocomplex exhibited intermediate superoxide anion production, maintaining levels comparable to control groups and demonstrating superior biocompatibility compared to magnetite and benzalkonium chloride alone. Testosterone levels remained unchanged following exposure to the Bc-coated nanoparticles. Collectively, these findings demonstrate that the Mag-Bc nanocomplex exhibits enhanced biocompatibility, characterized by a maintained cell viability, preserved cellular internalization capacity, reduced oxidative stress, and unchanged endocrine function. In contrast, cell growth kinetics of TM3 cells exposed to Bc-coated nanoparticles demonstrated reduced proliferation between days 3 and 8 compared with controls, suggesting potential time-dependent effects. The growth inhibition of Leydig cells induced by the nanocomplex may have implications for applications requiring suppression of testicular cell proliferation or for the development of nanoparticle-based therapeutic strategies targeting cell growth arrest.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.